Donitriptan (Pierre Fabre)

Curr Opin Investig Drugs. 2001 Mar;2(3):415-8.

Abstract

Pierre Fabre is developing donitriptan, a piperazide 5-HT1D agonist, as a potential treatment for migraine [175854]. In January 2001, donitriptan had completed phase I trials for migraine and was scheduled to enter phase II development [396027]. This compound has an increased potency and, importantly, markedly higher intrinsic activity in comparison to the well described tryptamine derivatives, naratriptan, zolmitriptan and sumatriptan [295769].

Publication types

  • Comparative Study

MeSH terms

  • Animals
  • Clinical Trials, Phase I as Topic
  • Drug Evaluation, Preclinical
  • Drugs, Investigational*
  • Humans
  • Migraine Disorders / drug therapy
  • Molecular Structure
  • Nitriles / chemistry
  • Nitriles / pharmacology*
  • Nitriles / therapeutic use
  • Nitriles / toxicity
  • Piperazines / chemistry
  • Piperazines / pharmacology*
  • Piperazines / therapeutic use
  • Piperazines / toxicity
  • Serotonin Receptor Agonists / chemistry
  • Serotonin Receptor Agonists / pharmacology*
  • Serotonin Receptor Agonists / therapeutic use
  • Tryptamines

Substances

  • Drugs, Investigational
  • Nitriles
  • Piperazines
  • Serotonin Receptor Agonists
  • Tryptamines
  • donitriptan